ESM Table 3

ESM Table 3. Clinical characteristics of the subjects from the rimonabant intervention study. Every measurement is presented as mean ± SEM (standard error of mean). Statistic: pairwise t-test (0 weeks vs. 48 weeks) within each group.

Drug	Placebo			Rimonabant		
Time	Before intervention (0 weeks)	After intervention (48 weeks)	p-value	Before intervention (0 weeks)	After intervention (48 weeks)	p-value
N (female)	8 (8)			12 (10)		
Age (years)	53.75 ± 3.38			51.50 ± 2.95		
Weight (kg)	81.39 ± 3.55	80.6 ± 4.61	0.7	99.93 ± 3.81	89.42 ± 3.12	0.00006
BMI (kg/m^2)	31.36 ± 1.53	31.01 ± 1.9	0.67	33.76 ± 0.76	30.25 ± 0.72	0.00003
Waist (cm)	101.25 ± 2.15	96 ± 2.72	0.01	111.82 ± 2.69	101.98 ± 1.95	0.00023
S-ALT (U/l)	36.25 ± 12.4	27.75 ± 7.21	0.38	26.25 ± 4.91	17.75 ± 1.56	0.05
S-AST (U/l)	33.63 ± 11.16	25 ± 3.76	0.29	23.42 ± 1.5	21.08 ± 1.14	0.17
fP-glucose (mmol/l)	5.53 ± 0.24	5.51 ± 0.19	0.94	5.51 ± 0.17	5.03 ± 0.45	0.34
fS-insulin (mU/l)	9.86 ± 1.86	10.60 ± 2.32	0.62	12.07 ± 1.71	7.27 ± 0.99	0.0013
Liver fat (%)	8.07 ± 2.51	7.1 ± 2.6	0.61	7.89 ± 2.12	1.32 ± 0.24	0.0089
Predicted liver fat (%)	3.42 ± 0.69	5.02 ± 1.07	0.31	4.69 ± 0.71	3.1 ± 0.45	0.043